BRAFMed

BRAFMed is an early-stage biotechnology company focused on developing next-generation targeted therapies for cancers driven by BRAF mutations. The company's primary research efforts center on overcoming resistance mechanisms associated with first-generation BRAF inhibitors, particularly in melanoma and colorectal cancer. By utilizing advanced medicinal chemistry, BRAFMed aims to design small molecules with improved selectivity and potency against both monomeric and dimeric forms of the BRAF kinase. Their current pipeline is in the discovery and pre-clinical validation phase, targeting high-unmet-need oncological indications.